Aridis Pharmaceuticals (NASDAQ:ARDS) released its earnings results on Tuesday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.12), Fidelity Earnings reports. The company had revenue of $1.02 million during the quarter.

Aridis Pharmaceuticals stock opened at $9.76 on Wednesday. Aridis Pharmaceuticals has a 52 week low of $7.59 and a 52 week high of $13.85. The stock has a market cap of $77.59 million and a P/E ratio of -1.39.

A number of analysts recently issued reports on ARDS shares. Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Aridis Pharmaceuticals in a research report on Wednesday, April 17th. Zacks Investment Research raised Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, April 2nd. Finally, Maxim Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Aridis Pharmaceuticals in a research report on Monday, April 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $27.50.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2019/05/15/aridis-pharmaceuticals-ards-releases-earnings-results-misses-expectations-by-0-12-eps.html.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

See Also: Why are gap-down stocks important?

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.